A detailed history of Washington Trust Advisors, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 29,485 shares of REGN stock, worth $30.7 Million. This represents 2.92% of its overall portfolio holdings.

Number of Shares
29,485
Previous 30,696 3.95%
Holding current value
$30.7 Million
Previous $29.5 Million 4.89%
% of portfolio
2.92%
Previous 2.79%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 25, 2024

SELL
$883.2 - $1071.19 $1.07 Million - $1.3 Million
-1,211 Reduced 3.95%
29,485 $31 Million
Q1 2024

May 07, 2024

SELL
$902.69 - $993.35 $1.38 Million - $1.52 Million
-1,529 Reduced 4.74%
30,696 $29.5 Million
Q4 2023

Jan 18, 2024

SELL
$775.18 - $881.7 $287,591 - $327,110
-371 Reduced 1.14%
32,225 $28.3 Million
Q3 2023

Oct 18, 2023

SELL
$692.45 - $844.37 $204,272 - $249,089
-295 Reduced 0.9%
32,596 $26.8 Million
Q2 2023

Jul 27, 2023

SELL
$700.03 - $830.35 $84,003 - $99,642
-120 Reduced 0.36%
32,891 $23.6 Million
Q1 2023

May 04, 2023

SELL
$680.49 - $826.97 $105,475 - $128,180
-155 Reduced 0.47%
33,011 $27.1 Million
Q4 2022

Feb 08, 2023

SELL
$705.89 - $766.39 $701,654 - $761,791
-994 Reduced 2.91%
33,166 $23.9 Million
Q3 2022

Oct 14, 2022

SELL
$573.97 - $724.32 $205,481 - $259,306
-358 Reduced 1.04%
34,160 $23.5 Million
Q2 2022

Jul 25, 2022

BUY
$548.35 - $738.84 $16,998 - $22,904
31 Added 0.09%
34,518 $20.4 Million
Q1 2022

May 05, 2022

SELL
$595.12 - $698.43 $249,355 - $292,642
-419 Reduced 1.2%
34,487 $24.1 Million
Q4 2021

Feb 11, 2022

BUY
$543.48 - $670.97 $19 Million - $23.4 Million
34,906 New
34,906 $22 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $112B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Washington Trust Advisors, Inc. Portfolio

Follow Washington Trust Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Washington Trust Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Washington Trust Advisors, Inc. with notifications on news.